The diagnostic landscape for Non-Small Cell Lung Cancer (NSCLC) is moving away from traditional biopsy towards a more holistic, molecular-first approach. As the most common form of lung cancer—accounting for nearly 85% of all cases—NSCLC diagnostics are the primary driver of innovation